EC grants marketing authorization to Meda's Zyclara for treatment of actinic keratosis

NewsGuard 100/100 Score
Aug 27 2012
Meda announced today that the European Commission (EC) has granted marketing authorization for Zyclara in the European Union. Zyclara (imiquimod 3.75% cream) is a patented product for the treatment of actinic keratosis. The approval is valid in all EU countries.

"Skin cancer is increasing and it is important to develop and improve the treatment of actinic keratosis. Zyclara is unique since it can treat large areas of the skin", said Anders Lönner, CEO of Meda AB.

Source:

MEDA

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

Diet's role in fighting vitiligo highlighted in new research
Study finds gut health key to combating skin diseases, eyes probiotics as potential treatment
Reversing time: Hyaluronic acid injections offer lasting improvement in aging skin
Women's skin study shows distinct chemical changes in response to psychological stress
MONET: New AI tool enhances medical imaging with deep learning and text analysis
Do you wear makeup while you exercise? New research reveals the effects on skin and pores
New study finds interferon-γ release assays more effective than skin tests in predicting tuberculosis
Childhood obesity not linked to adult skin cancer risk, study says

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Vitamin D deficiency persists despite easy access, review suggests need for tailored supplements